SOX9 and colorectal carcinoma: Importantly, using transcriptome data and pathway prediction, we found that SOX9, a novel CRC driver (32), not only was mechanistically involved in Gal-1/β-catenin interactions but also is a highly relevant biomarker, especially when evaluated in conjunction with Gal-1.